Ireland
--:--IST
Recruiting Phase 2

Reinforced Pancreaticojejunostomy With or Without glubran2

NCT06756074 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 2
Started
2025-01-15
Last updated
2026-03-16

Condition(s) studied

Pancreatic FistulaPancreas CancerPeriampullary CarcinomaPancreatic Ductal Adenocarcinoma

Investigational drug(s) / intervention(s)

Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2)Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)

Reinforced pancreaticojejunostomy with tissue adhesive glue modified cyanoacrylate (glubran 2): pancreaticojejunostomy was done with application of glubran 2: The blister pack was opened, and the sterile single-dose vial was released directly onto the operating table in a sterile environment, Draw the Glubran 2 out of the single-dose vial using a sterile syringe then put the syringe into applicator Glubran 2 was applied into anastomosis by applicator in spraying manner . Whenever possible, the area to be treated should be cleaned before application. When applied in such a minimal amount, once it had polymerized, Glubran 2 formed a thin adhesive layer. It was therefore essential not to apply more than one drop in the same point. A second layer of Glubran 2 may not be applied until the first had polymerized. Any excess product was removed using a dry swab within 5-6 seconds after application. Glubran 2 was not touched after application until the polymerization reaction is complete, as it may detach or not produce the desired effect.

Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2): Pancreaticojejunostomy without tissue adhesive glue modified cyanoacrylate (glubran 2)

Study summary

Pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. To reduce pancreatic fistula, many authors recommend different techniques in pancreatojejunostomy. The purpose of this study is to determine which is the best method in preventing pancreatic fistula by enforce pancreaticojejunostomy with tissue glue .

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * All the patients undergoing pancreaticoduodenectomy for cancer * Patients able to give their informed consent Exclusion Criteria: * Unfit patients for surgery due to severe medical illness. * Inoperable patients by imaging studies, irresectable tumors after laparotomy or diagnostic laparoscopy. * Presence of distant metastasis . * Patients refused to participate in the study.

Primary outcome measure(s)

  • the rate of Postoperative pancreatic fistula within 2 weeks after operation — within 2 weeks after operation
    Postoperative pancreatic fistula (POPF) is defined as a drain output of any measurable volume of fluid on or after postoperative day 3 with an amylase content greater than 3 times the serum amylase activity.

Trial sites (1)

FacilityCityRegionStatus
Liver and GIT hospital / Minia university Minya Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06756074 on ClinicalTrials.gov ↗ ← All trials in Egypt